# X4 Pharmaceuticals, Inc > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:8028bb9f-7f44-4154-bd59-b0d7fef01817 | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/x4-pharmaceuticals-inc | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 17 | | Claims under review | 1 | | Evidence records | 4 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-17T04:46:35.948617+00:00 | | Last reviewed | 2026-10-17T04:46:35.948617+00:00 | ## Identity - Legal name: X4 Pharmaceuticals, Inc - Display name: X4 Pharmaceuticals, Inc ## Alpha Governance Record | Field | Value | | --- | --- | | Governance Record schema | alpha-governance-record-v2 | | Ontology | alpha-governance-ontology-v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | As of | 2026-10-17T10:12:31.131507+00:00 | | Completeness | 0.409 | | Record Quality | 0.827 | | Directors | 5 | | Committees | 5 | | Governance events | 9 | | Entity class | public_company | ## Section coverage | Section | State | | --- | --- | | identity | PUBLISHED | | corporate_structure | NOT_REVIEWED | | board | PUBLISHED | | committees | PUBLISHED | | leadership | PUBLISHED | | ownership | NOT_REVIEWED | | financials | NOT_REVIEWED | | capital_structure | PUBLISHED | | compensation | NOT_REVIEWED | | governance | NOT_REVIEWED | | shareholder_governance | NOT_REVIEWED | | audit | NOT_REVIEWED | | legal | NOT_REVIEWED | | risk | NOT_REVIEWED | | cyber | NOT_REVIEWED | | ai_governance | NOT_REVIEWED | | agent_governance | RESTRICTED | | markets_external | NOT_REVIEWED | | events | PUBLISHED | | relationships | PUBLISHED | | assessments | PUBLISHED | | evidence | PUBLISHED | ## Board - Franoise De Craecker: Director. Status: current. Independent: true. Since: 2021-01-01. Committees: Audit (member); Audit; Compensation (member); Compensation (member). claim_id=alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:leadership_role:6 - Gary J. Bridger, Ph.D.: Director. Status: current. Independent: true. Since: 2018-01-01. claim_id=alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:leadership_role:7 - Michael S. Wyzga: Director. Status: current. Independent: true. Since: 2018-01-01. Committees: Audit (chair); Audit · Chair; Nominating and Governance · Chair (member); Nominating and Governance (chair). claim_id=alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:leadership_role:8 - Murray W. Stewart, M.D.: Director. Status: current. Independent: true. Since: 2019-01-01. claim_id=alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:leadership_role:9 - Adam R. Craig, M.D., Ph.D., M.B.A.: Director. Status: unknown. Independent: false. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:leadership_role:5 ## Committees - Audit (audit). Chair: Michael S. Wyzga. Members: Michael S. Wyzga (chair, current); Franoise De Craecker (member, current). committee_id=alpha:committee:x4-pharmaceuticals-inc:audit - Audit · Chair; Nominating and Governance · Chair (audit). Chair: NOT_PUBLISHED. Members: Michael S. Wyzga (member, current). committee_id=alpha:committee:x4-pharmaceuticals-inc:audit-chair-nominating-and-governance-chair - Audit; Compensation (audit). Chair: NOT_PUBLISHED. Members: Franoise De Craecker (member, current). committee_id=alpha:committee:x4-pharmaceuticals-inc:audit-compensation - Compensation (compensation). Chair: NOT_PUBLISHED. Members: Franoise De Craecker (member, current). committee_id=alpha:committee:x4-pharmaceuticals-inc:compensation - Nominating and Governance (nominating_governance). Chair: Michael S. Wyzga. Members: Michael S. Wyzga (chair, current). committee_id=alpha:committee:x4-pharmaceuticals-inc:nominating-and-governance ## Executive leadership - David Kirske: Chief Financial Officer, Treasurer and Corporate Secretary [CFO]. Status: current. claim_id=alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:leadership_role:10 ## Governance events - CFO_CHANGED: David Kirske executive of X4 Pharmaceuticals, Inc, effective 2026-03-20. Effective: 2026-03-20. Detected: 2026-10-17T04:46:35.948617+00:00. event_id=alpha:event:transition:zbof9y4te2vc - DIRECTOR_APPOINTED: Franoise De Craecker seat on X4 Pharmaceuticals, Inc, effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:46:35.948617+00:00. event_id=alpha:event:transition:p7bms61otku0o - COMMITTEE_CREATED: Audit; Compensation committee of X4 Pharmaceuticals, Inc, effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:46:35.948617+00:00. event_id=alpha:event:transition:1psywc01yourqk - COMMITTEE_MEMBER_ADDED: Franoise De Craecker member of Audit; Compensation, effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:46:35.948617+00:00. event_id=alpha:event:transition:1si23eb1809ypt - DIRECTOR_APPOINTED: Murray W. Stewart, M.D. seat on X4 Pharmaceuticals, Inc, effective 2019-01-01. Effective: 2019-01-01. Detected: 2026-10-17T04:46:35.948617+00:00. event_id=alpha:event:transition:raaizq1trstjo - DIRECTOR_APPOINTED: Gary J. Bridger, Ph.D. seat on X4 Pharmaceuticals, Inc, effective 2018-01-01. Effective: 2018-01-01. Detected: 2026-10-17T04:46:35.948617+00:00. event_id=alpha:event:transition:c4wssd1t9um0r - DIRECTOR_APPOINTED: Michael S. Wyzga seat on X4 Pharmaceuticals, Inc, effective 2018-01-01. Effective: 2018-01-01. Detected: 2026-10-17T04:46:35.948617+00:00. event_id=alpha:event:transition:1bfrra010giyao - COMMITTEE_CREATED: Audit · Chair; Nominating and Governance · Chair committee of X4 Pharmaceuticals, Inc, effective 2018-01-01. Effective: 2018-01-01. Detected: 2026-10-17T04:46:35.948617+00:00. event_id=alpha:event:transition:z0yfig1784tkg - COMMITTEE_MEMBER_ADDED: Michael S. Wyzga member of Audit · Chair; Nominating and Governance · Chair, effective 2018-01-01. Effective: 2018-01-01. Detected: 2026-10-17T04:46:35.948617+00:00. event_id=alpha:event:transition:ft58w01xuup1m ## Scoped resources - `alpha://company/x4-pharmaceuticals-inc` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record - `alpha://company/x4-pharmaceuticals-inc/identity` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=identity - `alpha://company/x4-pharmaceuticals-inc/corporate-structure` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=corporate-structure - `alpha://company/x4-pharmaceuticals-inc/board` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=board - `alpha://company/x4-pharmaceuticals-inc/committees` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=committees - `alpha://company/x4-pharmaceuticals-inc/leadership` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=leadership - `alpha://company/x4-pharmaceuticals-inc/ownership` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=ownership - `alpha://company/x4-pharmaceuticals-inc/financials` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=financials - `alpha://company/x4-pharmaceuticals-inc/capital-structure` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=capital-structure - `alpha://company/x4-pharmaceuticals-inc/compensation` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=compensation - `alpha://company/x4-pharmaceuticals-inc/governance` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=governance - `alpha://company/x4-pharmaceuticals-inc/shareholder-governance` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=shareholder-governance - `alpha://company/x4-pharmaceuticals-inc/audit` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=audit - `alpha://company/x4-pharmaceuticals-inc/legal` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=legal - `alpha://company/x4-pharmaceuticals-inc/risk` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=risk - `alpha://company/x4-pharmaceuticals-inc/cyber` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=cyber - `alpha://company/x4-pharmaceuticals-inc/ai-governance` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=ai-governance - `alpha://company/x4-pharmaceuticals-inc/agents` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=agents - `alpha://company/x4-pharmaceuticals-inc/ecosystem` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=ecosystem - `alpha://company/x4-pharmaceuticals-inc/events` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=events - `alpha://company/x4-pharmaceuticals-inc/relationships` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=relationships - `alpha://company/x4-pharmaceuticals-inc/assessments` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=assessments - `alpha://company/x4-pharmaceuticals-inc/evidence` (contract): https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record§ion=evidence ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - Claim alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:committee_appointment:12: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"chair","person":{"alpha_id":"alpha:person:michael-s-wyzga","name":"Michael S. Wyzga"},"source_id":"board_seats"}` - Claim alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:committee_appointment:13: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"member","person":{"alpha_id":"alpha:person:franoise-de-craecker","name":"Franoise De Craecker"},"source_id":"board_seats"}` - Claim alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:committee_appointment:15: `{"kind":"committee_appointment","original_name":"Compensation","category":"compensation","role":"member","person":{"alpha_id":"alpha:person:franoise-de-craecker","name":"Franoise De Craecker"},"source_id":"board_seats"}` - Claim alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:committee_appointment:17: `{"kind":"committee_appointment","original_name":"Nominating and Governance","category":"nominating_governance","role":"chair","person":{"alpha_id":"alpha:person:michael-s-wyzga","name":"Michael S. Wyzga"},"source_id":"board_seats"}` ## Leadership - Adam R. Craig, M.D., Ph.D., M.B.A.: Director. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:leadership_role:5. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:c5c3aeba0de7620d9e71ae69450be02a0a184ddb806c30e2dd039b4fd8c1dae3. - Franoise De Craecker: Director, Audit; Compensation. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:leadership_role:6. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:c5c3aeba0de7620d9e71ae69450be02a0a184ddb806c30e2dd039b4fd8c1dae3. - Gary J. Bridger, Ph.D.: Director. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:leadership_role:7. Valid from: 2018-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:c5c3aeba0de7620d9e71ae69450be02a0a184ddb806c30e2dd039b4fd8c1dae3. - Michael S. Wyzga: Director, Audit · Chair; Nominating and Governance · Chair. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:leadership_role:8. Valid from: 2018-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:c5c3aeba0de7620d9e71ae69450be02a0a184ddb806c30e2dd039b4fd8c1dae3. - Murray W. Stewart, M.D.: Director. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:leadership_role:9. Valid from: 2019-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:c5c3aeba0de7620d9e71ae69450be02a0a184ddb806c30e2dd039b4fd8c1dae3. - David Kirske: Chief Financial Officer, Treasurer and Corporate Secretary. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:leadership_role:10. Valid from: 2026-03-20. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:13a21d2fa22da7cb571068c3e2f2b4649791ce0c78f1ecb797efd501ca8c924a. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - Audit: Chair Michael S. Wyzga; Members Michael S. Wyzga (Chair); Franoise De Craecker. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:committee_record:11. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:e0c4cdf96a14659507e793e0ac14a1b99c664259c8257e480007000511e6348d. - Compensation: Chair not stated; Members Franoise De Craecker. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:committee_record:14. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:e0c4cdf96a14659507e793e0ac14a1b99c664259c8257e480007000511e6348d. - Nominating and Governance: Chair Michael S. Wyzga; Members Michael S. Wyzga (Chair). Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:committee_record:16. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:e0c4cdf96a14659507e793e0ac14a1b99c664259c8257e480007000511e6348d. ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - X4 Pharmaceuticals, Inc. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:919d21fd48c4711660d066afe6822461e772aede40975df9928d3f70afb67b68. ## Entity Status - Public listing published. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:919d21fd48c4711660d066afe6822461e772aede40975df9928d3f70afb67b68. ## Published Fact - US. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:919d21fd48c4711660d066afe6822461e772aede40975df9928d3f70afb67b68. ## Committee Appointment - Michael S. Wyzga: chair, Audit. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:committee_appointment:12. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:e0c4cdf96a14659507e793e0ac14a1b99c664259c8257e480007000511e6348d. - Franoise De Craecker: member, Audit. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:committee_appointment:13. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:e0c4cdf96a14659507e793e0ac14a1b99c664259c8257e480007000511e6348d. - Franoise De Craecker: member, Compensation. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:committee_appointment:15. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:e0c4cdf96a14659507e793e0ac14a1b99c664259c8257e480007000511e6348d. - Michael S. Wyzga: chair, Nominating and Governance. Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:committee_appointment:17. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:e0c4cdf96a14659507e793e0ac14a1b99c664259c8257e480007000511e6348d. ## Security Listing - XFOR (NASDAQ). Claim: alpha:claim:company:8028bb9f-7f44-4154-bd59-b0d7fef01817:security_listing:18. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:919d21fd48c4711660d066afe6822461e772aede40975df9928d3f70afb67b68. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:919d21fd48c4711660d066afe6822461e772aede40975df9928d3f70afb67b68: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/x4-pharmaceuticals-inc). - alpha:projection-evidence:document:c5c3aeba0de7620d9e71ae69450be02a0a184ddb806c30e2dd039b4fd8c1dae3: [X4 Pharmaceuticals, Inc DEF 14A 2026-03-20](https://www.sec.gov/Archives/edgar/data/1501697/000150169726000031/xfor-20260320.htm). - alpha:projection-evidence:document:13a21d2fa22da7cb571068c3e2f2b4649791ce0c78f1ecb797efd501ca8c924a: [XFOR DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1501697/000150169726000031/xfor-20260320.htm). - alpha:projection-evidence:e0c4cdf96a14659507e793e0ac14a1b99c664259c8257e480007000511e6348d: [Audit](https://www.sec.gov/Archives/edgar/data/1501697/000150169726000031/xfor-20260320.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/x4-pharmaceuticals-inc) - [Public Markdown](https://registry.alpha.ac/companies/x4-pharmaceuticals-inc.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/x4-pharmaceuticals-inc?format=jsonld) - MCP resource: `alpha://companies/x4-pharmaceuticals-inc` at https://mcp.alpha.ac/mcp ## Connected governance records Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage. ## Critical-risk oversight Snapshot as of 2026-10-17T10:12:30.92508+00:00; recorded 2026-10-17T10:12:30.92508+00:00. Every published assignment for this snapshot is listed. Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording. An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence.